Equity Profile

CPRX

Catalyst Pharmaceuticals, Inc.

Health CareBiotechnology$3.8B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Catalyst Pharmaceuticals, Inc. (CPRX) is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

$0.79

Revenue Growth

While specific revenue estimates are not available, any growth in revenue will indicate the company's ability to expand its market presence.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CPRX Q2-2026 Earnings Preview

Context

Company Snapshot

Catalyst Pharmaceuticals, Inc. (CPRX) is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases. With a market cap of $4 billion, it plays a significant role in the healthcare sector, particularly in addressing unmet medical needs.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+36.69%

Avg Stock Reaction

+0.67%

Last Quarter Recap

In Q1-2026, Catalyst Pharmaceuticals reported an EPS of $0.79, exceeding expectations by 36.21%. The stock did not move significantly the next day, indicating mixed investor sentiment.

Management Promises & Guidance

Continued focus on developing therapies for rare diseases.
Commitment to maintaining strong financial performance.
Plans to enhance market presence through strategic initiatives.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Catalyst's upcoming earnings, especially given its strong track record of beating EPS estimates.

Bull Case

If the company continues its trend of beating EPS estimates, it could see a positive reaction from the market, reinforcing investor confidence.

Bear Case

On the other hand, any signs of slowing revenue growth or failure to meet EPS expectations could lead to a negative market reaction.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.79

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

Revenue Growth

N/A

While specific revenue estimates are not available, any growth in revenue will indicate the company's ability to expand its market presence.

Market Reaction

N/A

The stock's immediate reaction post-earnings can provide insights into investor sentiment and confidence in the company's future.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed $0.79 this quarter?

A higher EPS would reinforce the company's strong performance and could lead to a positive market reaction.

What is the outlook for revenue growth moving forward?

Investors will be looking for guidance on revenue growth to assess the company's future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Catalyst's ability to sustain its earnings growth, especially given its recent performance and market positioning.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating strong operational execution.

Options pricing suggests a significant move, which may reflect underlying confidence in the company's prospects.

Key Risk

If the EPS comes in below $0.75, it could challenge the current bullish sentiment and lead to a reevaluation of the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The debate this quarter centers around whether Catalyst can maintain its strong earnings performance and revenue growth.

Bull Confirmed If

An EPS of $0.80 or higher would confirm the bullish case and likely lead to a positive market response.

Bear Confirmed If

An EPS below $0.75 would support the bearish case, raising concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±5.68%

Historical Avg

±1.4%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings announcement.

Options are pricing ±5.7% while CPRX has averaged ±1.4% over the last 8 prints — setup is pricing rich.

Detail

30d HV

36.4%

Calls (5K)P/C Ratio: 0.01Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Catalyst beats EPS expectations, history suggests the stock could rise by around 0.67% on the following day, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors digest the news.

Miss

A miss on EPS could lead to a decline of around 1.94%, reflecting disappointment among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new therapies in the pipeline.
2Details on market expansion strategies.
3Insights into competitive landscape and market share.
4Management's outlook on revenue growth for the next quarter.
5Responses to analyst questions regarding operational challenges.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Catalyst Pharmaceuticals, Inc. (CPRX) is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

$0.79

Revenue Growth

While specific revenue estimates are not available, any growth in revenue will indicate the company's ability to expand its market presence.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CPRX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+36.69%

Avg Stock Reaction

+0.67%

Last Quarter Recap

In Q1-2026, Catalyst Pharmaceuticals reported an EPS of $0.79, exceeding expectations by 36.21%. The stock did not move significantly the next day, indicating mixed investor sentiment.

Management Promises & Guidance

Continued focus on developing therapies for rare diseases.
Commitment to maintaining strong financial performance.
Plans to enhance market presence through strategic initiatives.

Expectations

Wall Street Expectations

Overall, investors are cautiously optimistic about Catalyst's upcoming earnings, especially given its strong track record of beating EPS estimates.

Bull Case

If the company continues its trend of beating EPS estimates, it could see a positive reaction from the market, reinforcing investor confidence.

Bear Case

On the other hand, any signs of slowing revenue growth or failure to meet EPS expectations could lead to a negative market reaction.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.79

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor this quarter.

Revenue Growth

N/A

While specific revenue estimates are not available, any growth in revenue will indicate the company's ability to expand its market presence.

Market Reaction

N/A

The stock's immediate reaction post-earnings can provide insights into investor sentiment and confidence in the company's future.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed $0.79 this quarter?

A higher EPS would reinforce the company's strong performance and could lead to a positive market reaction.

What is the outlook for revenue growth moving forward?

Investors will be looking for guidance on revenue growth to assess the company's future prospects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Catalyst's ability to sustain its earnings growth, especially given its recent performance and market positioning.

Supporting Evidence

The company has consistently beaten EPS estimates, indicating strong operational execution.

Options pricing suggests a significant move, which may reflect underlying confidence in the company's prospects.

Key Risk

If the EPS comes in below $0.75, it could challenge the current bullish sentiment and lead to a reevaluation of the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The debate this quarter centers around whether Catalyst can maintain its strong earnings performance and revenue growth.

Bull Confirmed If

An EPS of $0.80 or higher would confirm the bullish case and likely lead to a positive market response.

Bear Confirmed If

An EPS below $0.75 would support the bearish case, raising concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±5.68%

Historical Avg

±1.4%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings announcement.

Options are pricing ±5.7% while CPRX has averaged ±1.4% over the last 8 prints — setup is pricing rich.

Detail

30d HV

36.4%

Calls (5K)P/C Ratio: 0.01Puts (0)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Catalyst beats EPS expectations, history suggests the stock could rise by around 0.67% on the following day, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors digest the news.

Miss

A miss on EPS could lead to a decline of around 1.94%, reflecting disappointment among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new therapies in the pipeline.
2Details on market expansion strategies.
3Insights into competitive landscape and market share.
4Management's outlook on revenue growth for the next quarter.
5Responses to analyst questions regarding operational challenges.